AzTrials
AzTrials

Obesity, AbdominalMHIPNCT05972109

Metabolic Health Improvement Program: Effects of a Workplace Sugary Beverages Sales Ban and Motivational Counseling

A study testing Workplace SSB sales ban and Brief Intervention in people with Obesity, Abdominal and Insulin Sensitivity, run by University of California, San Francisco at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the study is to test the impact of a multilevel workplace intervention (hospital-wide sales ban on sugar-sweetened beverages (SSBs) and individual-level brief counseling) on employee health. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Obesity, Abdominal, Insulin Sensitivity
What is being tested?
Workplace SSB sales ban and Brief Intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
604 participants
Where
1 siteUnited States
Study dates
1 Aug 2023to 1 Feb 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Full-time employee who works on campus at one of the Sutter Health participating sites
  • Speaks and reads English
  • Consumes three or more sugar-sweetened beverages (SSB) a week
  • Agrees to participate in two fasting blood draws

Who cannot join

  • Pregnant

Trial locations and contacts

1 site in 1 country.

United States1 site

  • Sutter Health/California Pacific Medical Center Research Institute

    San Francisco, California, 94115

Other trials in United States

About this study

Official title: Multi-Level Trial of a Workplace Sales Ban of Sugary Beverages and Brief Motivational Counseling Intervention on Adiposity

The purpose of the study is to test the impact of a multilevel workplace intervention (hospital-wide sales ban on sugar-sweetened beverages (SSBs) and individual-level brief counseling) on employee health.

Read the detailed description

This double-randomized controlled trial of a multilevel workplace intervention that combines an employer-sponsored sales ban on sugar-sweetened beverages (SSBs) with brief counseling to support reduced consumption will test how well each intervention works alone, whether they work better in combination than separately, and whether or not changes in SSB cravings mediate these effects. Sutter Health worksites will be randomly assigned to either a control condition or to implement a sales ban on SSBs. Within all sites, employees will be randomized to receive/not receive a brief counseling intervention focused on reducing SSB consumption. Participants will complete self-report questionnaires, give blood samples, and provide measurements of waist circumference, height, and weight. These data will be analyzed to determine the effects of the interventions, both separately and in combination.

Being tested
Workplace SSB sales ban, Brief Intervention
Medical subject headings
Obesity, Abdominal, Insulin Resistance

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Workplace SSB sales banOther

    Environmental Intervention. The hospital food services will replace sugary drinks with non-sugar added alternative beverages throughout the campus.

  • Brief InterventionBehavioural

    Participants receive single-session brief intervention, which is an intervention that uses motivational interviewing, and helps participants understand amount and effect of their baseline SSB intake, identify realistic goals for reduction and overcoming obstacles.

Study groups in NCT05972109
Study groupRoleWhat they receive
Control: No workplace SSB sales ban, no brief interventionNo interventionParticipants receive no workplace SSB sales ban (environmental intervention) and no brief counseling intervention.
Workplace SSB sales ban onlyExperimentalParticipants receive a workplace SSB sales ban (environmental intervention). This entails the removal of SSBs from all workplace sales outlets, replacing them with non-sugary beverage options.
Receives: Other: Workplace SSB sales ban
Brief intervention onlyExperimentalParticipants receive a 20-30 minute intervention by video call, with 2 booster telephone calls. One week and one month after the initial session, participants will have 10-minute check-in/booster phone calls.
Receives: Behavioral: Brief Intervention
Multilevel Intervention (workplace SSB sales ban + brief intervention)ExperimentalSales ban: Participants receive a workplace SSB sales ban (environmental intervention). This entails the removal of SSBs from all workplace sales outlets, replacing them with non-sugary beverage options. Brief Intervention: Participants receive a 20-30 minute intervention by video call, with 2 booster telephone calls. One week and one month after the initial session, participants will have 10-minute check-in/booster phone calls.
Receives: Other: Workplace SSB sales ban; Behavioral: Brief Intervention

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Abdominal Adiposity (Waist Circumference)

    Waist circumference in centimeters (using method from Multi-Ethnic Study of Atherosclerosis). The study will measure the change between baseline and 12 month Abdominal Adiposity measurements.

    Measured: Baseline and 12 Months

  2. Change in Insulin Sensitivity (HOMA)

    Insulin sensitivity will be calculated using the homeostatic model assessment (HOMA). The equation for HOMA is fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. The study will measure the change between baseline and 12 month HOMA.

    Measured: Baseline and 12 Months

Secondary outcomes (6)

  1. Change in Body Mass Index (BMI)

    Body Mass Index [BMI] measured using height in centimeters and weight in kilograms to be calculated into BMI. The study will measure the change between baseline and 12 month BMI.

    Measured: Baseline and 12 Months

  2. Change in Quantity of SSB Consumption

    Fluid ounces of SSB consumed per day using Automated Self-Administered Dietary Assessment Tool (ASA-24) and Beverage Intake Questionnaire (BEV-Q). The study will measure the change between baseline and 12 month SSB consumption quantity.

    Measured: Baseline and 12 Months

  3. Change in Lipid Profile Measurements

    HDL, LDL, total cholesterol, triglycerides, and triglycerides:HDL ratio (calculated). The study will measure the change between baseline and 12 month individual lipid profile measurements (E.g., HDL, LDL, total cholesterol, triglycerides, and triglycerides:HDL ratio).

    Measured: Baseline and 12 Months

  4. Change in ApoB Levels

    Blood level of ApoB. The study will measure the change between baseline and 12 month ApoB blood levels.

    Measured: Baseline and 12 Months

  5. Change in Fasting insulin Levels

    Fasting blood level of insulin. The study will measure the change between baseline and 12 month Fasting insulin blood levels.

    Measured: Baseline and 12 Months

  6. Change in Fasting Glucose Levels

    Fasting blood level of glucose. The study will measure the change between baseline and 12 month Fasting Glucose blood levels.

    Measured: Baseline and 12 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Aug 2023
  2. Study start1 Aug 2023
  3. Primary completion1 Dec 2025
  4. Study completion1 Feb 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Factorial
Model description
The study is a double-randomized, controlled trial of 700 Sutter Health employees working at 16 hospital campuses. The hospital campuses will be randomized to sales ban or control. After screening employees at the 16 campuses for heavy SSB consumption (\> 30 oz/week), the investigators will further randomize study participants to receive the brief counseling intervention or not. This will result in a balanced design of n=175 participants in each cell of a 2x2 factorial design: 1) sales ban alone; 2) behavioral counseling alone, 3) combined condition of sales ban and behavioral counseling, and 4) no intervention or control condition. This is an efficient design for testing the effects of the sales ban and brief counseling interventions plus their cross-level interaction within a context of full randomization.
Masking
None (open label)
Enrolment
604 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05972109
Sponsor's protocol ID
22-38247
Other IDs
R01DK132870
Acronym
MHIP
Status last verified
Feb 2026
First submitted
25 Jul 2023
Last updated
23 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Workplace SSB sales ban and Brief Intervention in people with Obesity, Abdominal and Insulin Sensitivity, run by University of California, San Francisco at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Abdominal Adiposity (Waist Circumference) (time frame: Baseline and 12 Months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05972109.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in